

Sheet 1 of 2

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. P33027USW	SERIAL NO. 10/508,761
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Giblin et al.	
		FILING DATE Sept. 22, 2004	GROUP 1625

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

<i>BMC</i>	2	AHMAD, ET AL.: Prostaglandin EP1 Receptor Contributes to Excitotoxicity and Focal Ischemic Brain Damage; <i>Toxicological Sciences</i> ; October 19, 2005; 69(1): 265-270; Oxford University Press;
<i>BMC</i>	3	KAWAHARA, ET AL.: A Prostaglandin E2 Receptor Subtype EP1 Receptor Antagonist (ONO-8711) Reduces Hyperalgesia, Allodynia, and C-fos Gene Expression in Rats with Chronic Nerve Constriction; <i>Anesth Analg</i> ; 2001; 93: 1012-7; International Anesthesia Research Society;
<i>BMC</i>	4	KAWANO, ET AL.: Prostaglandin E2 EP1 Receptors: Downstream Effectors of Cox-2 Neurotoxicity; <i>Nature Medicine</i> ; February 2005; 12(2): 225-229; Nature Publishing Group;
<i>BMC</i>	5	OMOTE, ET AL.: The Effects of Intrathecal Administration of an Antagonist for Prostaglandin E Receptor Subtype EP1 on Mechanical and Thermal Hyperalgesia in a Rat Model of Postoperative Pain; <i>Anesth Analg</i> ; 2002; 95: 1708-12; International Anesthesia Research Society;
<i>BMC</i>	6	OMOTE, ET AL.: The Effects of Peripheral Administration of a Novel Selective Antagonist for Prostaglandin E Receptor Subtype EP1, ONO-8711, in a Rat Model of Postoperative Pain; <i>Anesth Analg</i> ; 2001; 92: 233-6; International Anesthesia Research Society;
	7	SARKAR, ET AL.: The Prostaglandin E2 Receptor-1 (EP1) Mediates Acid-Induced Visceral Pain hypersensitivity in Humans; <i>Gastroenterology</i> ; 2003; 124: 18-25; American Gastroenterological Association;

Examiner Signature	Binta Johnson	Date Considered	1/26/07
--------------------	---------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2

Form PTO-1448	U.S. Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. PS9027USW	SERIAL NO. 10/508,761
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Giblin et al.	
		FIILING DATE Sept. 22, 2004	GROUP 1625

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc)

BR	8	STOCK, ET AL.; The Prostaglandin E2 EP1 Receptor Mediates Pain Perception and Regulates Blood Pressure; <i>The Journal of Clinical Investigation</i> ; February 2001; 107(3): 325-331;

Examiner Signature /Binta Robinson/	Date Considered 01/26/2007
---	--------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER TO-1449 INFORMATION DISCLOSURE STATEMENT		SERIAL NO.	10/508,761
		FILING DATE	September 22, 2004
		APPLICANT	Giblin et al.
		GROUP	1615
		EXAMINER	
		ATTORNEY DOCKET NO.	P33027USW

APR 25 2005
PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS						
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass
	1	6,495,149	Dec. 17, 2002	Scavone et al.		
	2	6,440,963	Aug. 27, 2002	Leonardi et al.		
	3	US 2002 045605	Apr. 18, 2002	Kargman et al.		
	4	6,136,839	Oct. 24, 2000	Isakson et al.		
	5	5,972,986	Oct. 26, 1999	Seibert et al.		
	6	5,840,746	Nov. 24, 1998	Ducharme et al.		
	7	5,663,180	Sept. 2, 1997	Reitz et al.		
	8	5,474,995	Dec. 12, 1995	Ducharme et al.		
	9	5,344,991	Sept. 6, 1994	Reitz et al.		
BMK	10	5,420,287	May 30, 1995	Reitz, et al.		

Continue on page 2

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
BMK	13	EP 1264847	Dec. 11, 2002	EUROPE			Abstract only
BMK	14	JP 2002363748	Dec. 18, 2002	JAPAN			Abstract only
BMK	15	WO 02/099435	Dec. 12, 2002	WIPO			
BMK	16	EP 1251126	Oct. 23, 2002	EUROPE			
BMK	17	WO 01/081332	Nov. 1, 2001	WIPO			
BMK	18	WO 00/53149	Sept. 14, 2000	WIPO			
BMK	19	WO 00/47553	Aug. 17, 2000	WIPO			
BMK	20	WO 99/58487	Nov. 19, 1999	WIPO			
BMK	21	WO 99/17776	Apr. 15, 1999	WIPO			
BMK	22	WO 98/55468	Dec. 10, 1998	WIPO			
BMK	23	WO 98/16227	Apr. 23, 1998	WIPO			
BMK	24	WO 97/16435	May 9, 1997	WIPO			
BMK	25	WO 97/11701	Apr. 3, 1997	WIPO			
BMK	26	WO 97/03667	Feb. 6, 1997	WIPO			
BMK	27	WO 96/41645	Dec. 27, 1996	WIPO			
BMK	28	WO 96/36623	Nov. 21, 1996	WIPO			
BMK	29	WO 96/11676	Apr. 25, 1996	WIPO			
BMK	30	WO 95/00501	Jan. 5, 1995	WIPO			
BMK	31	WO 95/17393	June 29, 1995	WIPO			
BMK	32	WO 95/05372	Feb. 23, 1995	WIPO			

Continue on page 2

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

BMK	58	Whitesell, J.K., et al. "Synthesis and Resolution of a New Chiral C2-Symmetric Bisphenol: Trans-1,2-Bis(2-Hydroxyphenyl)cyclopentane." <i>Tetrahedron Letters</i> , 1997, 38(15), pgs. 2589-2592.
BMK	59	Rathore, R., et al. "Efficient Hydrogenation of Sterically Hindered Olefins with Borane-Methyl Sulfide Complex." <i>Journal of Organic Chemistry</i> , 1996, 61(16), pgs. 5246-5256.
BMK	60	Malik, O.P., et al. "Studies on Cannabinoids: Part III. Synthesis of 9,10,11,11a-Tetrahydro-6H,8H-Pyrido[1,2-c][1,3]benzoxazine." <i>Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry</i> , 1976, 14B(12), pgs 975-978.

Continue on page

EXAMINER

DATE CONSIDERED

8/17/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	SERIAL NO. 10/508,761
	FILING DATE September 22, 2004
	APPLICANT Ciblin et al.
	GROUP 1615
	EXAMINER
	ATTORNEY DOCKET NO. P33027USW

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
<i>Boswell</i>	11	5,512681	Apr. 30, 1996	Boswell et al.			
<i>Boswell</i>	12	5,424,450	June 13, 1995	Boswell et al.			

Continue on page

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
		Document Number	Publication Date	Country	Class	Subclass
BWIK	33	GB 2,272,899	June 1, 1994	GREAT BRITAIN		
BWIK	34	JP 06065213	March 8, 1994	JAPAN		Abstract only
BWIK	35	JP 05224442	Sept. 3, 1993	JAPAN		Abstract only
BWIK	36	EP 540009	May 5, 1993	EUROPE		
BWIK	37	JP 04076087	March 10, 1992	JAPAN		Abstract only
BWIK	38	DE 4034728	May 7, 1992	GERMANY		Abstract only
BWIK	39	DE 4032522	Apr. 16, 1992	GERMANY		Abstract only
BWIK	40	WO 97/38986	Oct. 23, 1997	WIPO		
BWIK	41	WO 95/11883	May 4, 1995	WIPO		
BWIK	42	WO 96/37496	Nov. 28, 1996	WIPO		
BWIK	43	WO 94/05658	Mar. 17, 1994	WIPO		
BWIK	44	JP 04235933	Aug. 25, 1992	JAPAN		Abstract only
BWIK	45	EP 131302	Jan. 16, 1985	EUROPE		
BWIK	46	AU 8311483	Mar. 3, 1982	AUSTRALIA		Abstract only
BWIK	47	EP 52300	Nov. 13, 1980	EUROPE		Abstract only
BWIK	48	DT 2405171	Feb. 19, 1979	GERMANY		Abstract only
BWIK	49	NE 6610022	Aug. 2, 1965	NIGER		Abstract only
BWIK	50	BEL 611179	Dec. 6, 1960	BELGIUM		X
BWIK	51	DE 20211496	Nov. 19, 2002	GERMANY		Abstract only
BWIK	52	WO 98/25896	June 18, 1998	WIPO		
BWIK	53	EP 0799823	Oct. 8, 1997	EUROPE		
BWIK	54	WO 01/19814	Mar. 22, 2001	WIPO		
BWIK	55	WO 93/04045	Mar. 4, 1993	WIPO		
BWIK	56	WO 93/04046	Mar. 4, 1993	WIPO		
BWIK	57	WO 00/59506	Oct. 12, 2000	WIPO		

Continue on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

Continue on page

EXAMINER		DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.		